Not Yet Recruiting EARLY_PHASE1 INTERVENTIONAL 2-arm
NCT06810869
Induced Pluripotent Stem Cell Derived Exosomes Nasal Drops for the Treatment of Stable Vitiligo
Exploratory Clinical Study on Induced Pluripotent Stem Cell Derived Exosomes (iPSC-Exos) for the Treatment of Stable Vitiligo
Sponsor: Guidon Pharmaceutics Ltd.
Conditions
Stable Vitiligo
Interventions
a placebo of exosomes derived from human induced pluripotent stem cell for injection human induced pluripotent stem cell derived exosomes （GD-iExo-003）
Updated 1 time since 2025 Last updated: Feb 1, 2025 Started: Feb 5, 2025 Primary completion: Nov 17, 2026 Completion: Nov 17, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
Listed as NCT06810869, this EARLY_PHASE1 trial focuses on Stable Vitiligo and remains actively recruiting participants. Sponsored by Guidon Pharmaceutics Ltd., it has been updated 1 time since 2025, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
1 version recorded Not Yet Recruiting — EARLY_PHASE1
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Guidon Pharmaceutics Ltd.
- Second Affiliated Hospital of Wannan Medical College
Data source: Second Affiliated Hospital of Wannan Medical College
For direct contact, visit the study record on ClinicalTrials.gov .